Boulder-based Array BioPharma (NASDAQ:ARRY) inked a clinical research collaboration with Bristol-Myers Squibb on a potential treatment for colorectal cancer patients using a combination of the two companies’ drugs, BMS’s Opdivo (nivolumab) in combination with Array’s binimetinib.
Array received the rights to binimetinib after a 2015 drug assets swap between Novartis and GlaxoSmith Kline. The drug has been studied in patients with ovarian cancer and melanoma, and in February Array announced its intention to file an application for the COLUMBUS melanoma treatment, which is a combination of binimetinib and encorafenib.
COLUMBUS trials were achieving positive results in early May, the company announced. A new drug filing is on schedule for June or July.
The partnership with Bristol-Myers Squibb was announced Tuesday. Array will sponsor the clinical trial, with BMS supporting. The study is expected to begin in the second half of 2017.
